Myocardial reinfarction prevention in patient at high risk of gastric ulcer risk

This clinical indication represents a dual-management scenario involving secondary cardiovascular prophylaxis alongside gastroprotection in patients with established coronary artery disease It defines individuals who have sustained a prior myocardial infarction and require long-term antiplatelet therapy to suppress recurrent coronary thrombosis, but who concurrently possess high susceptibility to gastric mucosal injury, such as patients aged 55 or older or those with a documented history of pept...

This clinical indication represents a dual-management scenario involving secondary cardiovascular prophylaxis alongside gastroprotection in patients with established coronary artery disease Pathophysiologically, maintaining coronary patency relies on platelet cyclooxygenase-1 inhibition, an effect that concurrently impairs protective gastric prostaglandin synthesis, disrupts the mucosal barrier, and elevates gastric acid–mediated ulceration and hemorrhage risk

Pathophysiologically, maintaining coronary patency relies on platelet cyclooxygenase-1 inhibition, an effect that concurrently impairs protective gastric prostaglandin synthesis, disrupts the mucosal barrier, and elevates gastric acid–mediated ulceration and hemorrhage risk

Consequently, this clinical state encompasses cardiovascular risk mitigation paired with mucosal defense strategies to prevent fatal or nonfatal reinfarction while mitigating drug-associated upper gastrointestinal toxicity